Advertisement
Original Article| Volume 62, ISSUE 6, P1165-1174, December 2021

Download started.

Ok

Efficacy of Proportional Sedation and Deep Sedation Defined by Sedation Protocols: A Multicenter, Prospective, Observational Comparative Study

      Abstract

      Purpose

      To investigate the efficacy of two types of palliative sedation: proportional and deep sedation, defined by sedation protocols.

      Methods

      From a multicenter prospective observational study, we analyzed the data of those patients who received the continuous infusion of midazolam according to the sedation protocol. The primary endpoint was goal achievement at 4 hours: in proportional sedation, symptom relief (Integrated Palliative care Outcome Scale: IPOS ≤ 1) and absence of agitation (modified Richmond Agitation-Sedation Scale: RASS ≤ 0); in deep sedation, the achievement of deep sedation (RASS ≤ -4). Secondary endpoints included deep sedation as a result of proportional sedation, communication capacity (Communication Capacity Scale item 4 ≤ 2), IPOS and RASS scores, and adverse events.

      Results

      A total of 81 patients from 14 palliative care units were analyzed: proportional sedation (n = 64) and deep sedation (n = 17). At 4 hours, the goal was achieved in 77% (n = 49; 95% confidence interval: 66-87) with proportional sedation; and 88% (n = 15; 71-100) with deep sedation. Deep sedation was necessary in 45% of those who received proportional sedation. Communication capacity was maintained in 34% with proportional sedation and 10% with deep sedation. IPOS decreased from 3.5 to 0.9 with proportional sedation, and 3.5 to 0.4 with deep sedation; RASS decreased from +0.3 to -2.6, and +0.4 to -4.2, respectively. Fatal events related to the treatment occurred in 2% (n = 1) with proportional and none with deep sedation.

      Conclusion

      Proportional sedation achieved satisfactory symptom relief while maintaining some patients’ consciousness, and deep sedation achieved good symptom relief while the majority of patients lost consciousness.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pain and Symptom Management
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Beller EM
        • van Driel ML
        • McGregor L
        • et al.
        Palliative pharmacological sedation for terminally ill adults.
        Cochrane Database Syst Rev. 2015; 1CD010206
        • Arantzamendi M
        • Belar A
        • Payne S
        • et al.
        Clinical aspects of palliative sedation in prospective studies. A systematic review.
        J Pain Symptom Manage. 2020; 20: 30754-30755
        • de Graeff A
        • Dean M.
        Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards.
        J Palliat Med. 2007; 10: 67-85
        • Schildmann E
        • Schildmann J.
        Palliative sedation therapy: a systematic literature review and critical appraisal of available guidance on indication and decision making.
        J Palliat Med. 2014; 17: 601-611
        • Abarshi E
        • Rietjens J
        • Robijn L
        • et al.
        International variations in clinical practice guidelines for palliative sedation: a systematic review.
        BMJ Support Palliat Care. 2017; 7: 223-229
        • Cherny NI
        • ESMO Guidelines Working Group
        ESMO clinical practice guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation.
        Ann Oncol. 2014; 25: iii143-iii152
        • Cherny NI
        • Radbruch L
        • Board of the European Association for Palliative Care
        European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care.
        Palliat Med. 2009; 23: 581-593
      1. The Haute Autorité de Santé Board. CARE PATHWAY GUIDE How to implement continuous deep sedation until death? 2018. Available at: https://www.has-sante.fr/upload/docs/application/pdf/2018-11/care_pathway_guide_how_to_implement_continuous_deep_sedation_until_death.pdf. Accessed May 17, 2021.

        • Quill TE
        • Lo B
        • Brock DW
        • et al.
        Last-resort options for palliative sedation.
        Ann Intern Med. 2009; 151: 421-424
        • Swart SJ
        • van der Heide A
        • van Zuylen L
        • et al.
        Considerations of physicians about the depth of palliative sedation at the end of life.
        CMAJ. 2012; 184: E360-E366
        • Morita T
        • Imai K
        • Yokomichi N
        • et al.
        Continuous deep sedation: a proposal for performing more rigorous empirical research.
        J Pain Symptom Manage. 2017; 53: 146-152
        • Imai K
        • Morita T
        • Akechi T
        • et al.
        The principles of revised clinical guidelines about palliative sedation therapy of the Japanese Society for Palliative Medicine.
        J Palliat Med. 2020; 23: 1184-1190
        • Hamano J
        • Morita T
        • Ikenaga M
        • et al.
        A nationwide survey about palliative sedation involving Japanese palliative care specialists: intentions and key factors used to determine sedation as proportionally appropriate.
        J Pain Symptom Manage. 2018; 55: 785-791
        • Imai K
        • Morita T
        • Yokomichi N
        • et al.
        Efficacy of two types of palliative sedation therapy defined using intervention protocols: proportional vs. deep sedation.
        Support Care Cancer. 2018; 26: 1763-1771
        • Yamaguchi T
        • Maeda I
        • Hatano Y
        • et al.
        Communication and behavior of palliative care physicians of patients with cancer near end of life in three East Asian countries.
        J Pain Symptom Manage. 2021; 61: 315-322
        • Mori M
        • Kawaguchi T
        • Imai K
        • et al.
        How successful is parenteral oxycodone for relieving terminal cancer dyspnea compared with morphine? A multicenter prospective observational study.
        J Pain Symptom Manage. 2020; 5 (3924(20)30931-3. Online ahead of print)https://doi.org/10.1016/j.jpainsymman.2020.11.037
        • Schildmann EK
        • Schildmann J
        • Kiesewetter I.
        Medication and monitoring in palliative sedation therapy: a systematic review and quality assessment of published guidelines.
        J Pain Symptom Manage. 2015; 49: 734-746
        • Jacobi J
        • Fraser GL
        • Coursin DB
        • et al.
        Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult.
        Crit Care Med. 2002; 30: 119-141
        • Pecking M
        • Montestruc F
        • Marquet P
        • et al.
        Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers.
        Br J Clin Pharmacol. 2002; 54: 357-362
        • Zomorodi K
        • Donner A
        • Somma J
        • et al.
        Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting.
        Anesthesiology. 1998; 89: 1418-1429
        • Albrecht S
        • Ihmsen H
        • Hering W
        • et al.
        The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
        Clin Pharmacol Ther. 1999; 65: 630-639
        • Murtagh FE
        • Ramsenthaler C
        • Firth A
        • et al.
        A brief, patient- and proxy-reported outcome measure in advanced illness: validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS).
        Palliat Med. 2019; 33: 1045-1057
        • Sakurai H
        • Miyashita M
        • Imai K
        • et al.
        Validation of the Integrated Palliative care Outcome Scale (IPOS) - Japanese version.
        Jpn J Clin Oncol. 2019; 49: 257-262
        • Sessler CN
        • Gosnell MS
        • Grap MJ
        • et al.
        The richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients.
        Am J Respir Crit Care Med. 2002; 166: 1338-1344
        • Benítez-Rosario MA
        • Castillo-Padrós M
        • Garrido-Bernet B
        • et al.
        Appropriateness and reliability testing of the modified Richmond Agitation-Sedation Scale in Spanish patients with advanced cancer.
        J Pain Symptom Manage. 2013; 45: 1112-1119
        • Imai K
        • Morita T
        • Mori M
        • et al.
        Development and linguistic validation of the Japanese version of the modified Richmond Agitation-Sedation Scale.
        Palliat Care Res. 2016; 11 (in Japanese): 331-336
        • Morita T
        • Tsunoda J
        • Inoue S
        • et al.
        Communication Capacity Scale and Agitation Distress Scale to measure the severity of delirium in terminally ill cancer patients: a validation study.
        Palliative Med. 2001; 15: 197-206
        • Oken M
        • Creech R
        • Tormey D
        • et al.
        Toxicity and response criteria of the Eastern Cooperative Oncology Group.
        Am J Clin Oncol. 1982; 5: 649-655
        • Gwilliam B
        • Keeley V
        • Todd C
        • et al.
        Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study.
        BMJ Support Palliat Care. 2015; 5: 390-398
        • Sykes N
        • Thorns A.
        The use of opioids and sedatives at the end of life.
        Lancet Oncol. 2003; 4: 312-318
        • Morita T
        • Chinone Y
        • Ikenaga M
        • et al.
        Ethical validity of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan.
        J Pain Symptom Manage. 2005; 30: 308-319
        • Won YW
        • Chun HS
        • Seo M
        • et al.
        Clinical patterns of continuous and intermittent palliative sedation in patients with terminal cancer: a descriptive, observational study.
        J Pain Symptom Manage. 2019; 58: 65-71
        • Maeda I
        • Morita T
        • Yamaguchi T
        • et al.
        Effect of continuous deep sedation on survival in patients with advanced Cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study.
        Lancet Oncol. 2016; 17: 115-122
        • Maltoni M
        • Pittureri C
        • Scarpi E
        • et al.
        Palliative sedation therapy does not hasten death: results from a prospective multicenter study.
        Ann Oncol. 2009; 20: 1163-1169
        • Maltoni M
        • Scarpi E
        • Rosati M
        • et al.
        Palliative sedation in end-of-life care and survival: a systematic review.
        J Clin Oncol. 2012; 30: 1378-1383
        • Papavasiliou ES
        • Brearley SG
        • Seymour JE
        • et al.
        From sedation to continuous sedation until death: how has the conceptual basis of sedation in end-of-life care changed over time?.
        J Pain Symptom Manage. 2013; 5: 706-723
        • Rys S
        • Mortier F
        • Deliens L
        • et al.
        Continuous sedation until death: moral justifications of physicians and nurses-a content analysis of opinion pieces.
        Med Health Care Philos. 2013; 16: 533-542
        • Quill TE.
        The ambiguity of clinical intentions.
        N Engl J Med. 1993; 329: 1039-1040
        • Jansen LA.
        Disambiguating clinical intentions: the ethics of palliative sedation.
        J Med Philos. 2010; 35: 19-31
        • Morita T
        • Chinone Y
        • Ikenaga M
        • et al.
        Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan.
        J Pain Symptom Manage. 2005; 30: 320-328
        • Matsuo N
        • Morita T.
        Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study.
        J Palliat Med. 2007; 10: 1054-1062